Last reviewed · How we verify
G-CSF and NAC
At a glance
| Generic name | G-CSF and NAC |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
- Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC
- Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis (PHASE4)
- G-CSF Plus NAC In Severe Alcoholic Hepatitis (PHASE4)
- Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- G-CSF and NAC CI brief — competitive landscape report
- G-CSF and NAC updates RSS · CI watch RSS
- Post Graduate Institute of Medical Education and Research, Chandigarh portfolio CI